Krystal Biotech, Inc.
NASDAQ:KRYS
155.81 (USD) • At close January 6, 2025
Overzicht | Financiële gegevens
Cijfers zijn in miljoenen (behalve de cijfers per aandeel en de ratio's) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|
| Omzet
| 50.699 | 0 | 0 | 0 | 0 | 1.027 | 0 | 0 |
| Kosten van de omzet
| 3.094 | 4.055 | 2.769 | 1.851 | 0.974 | 0.141 | 0.023 | 0.002 |
| Brutowinst
| 47.605 | -4.055 | -2.769 | -1.851 | -0.974 | 0.886 | -0.023 | -0.002 |
| Brutowinstmarge
| 0.939 | 0 | 0 | 0 | 0 | 0.863 | 0 | 0 |
| Onderzoek- en ontwikkelingskosten
| 46.431 | 42.461 | 27.884 | 17.936 | 15.616 | 7.761 | 3.208 | 0.741 |
| Algemene en administratieve kosten
| 0 | 77.735 | 40.391 | 15.063 | 6.465 | 4.155 | 1.564 | 0.402 |
| Verkoop- en marketingkosten
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Verkoop-, algemene en administratieve kosten
| 98.401 | 77.735 | 40.391 | 15.063 | 6.465 | 4.155 | 1.564 | 0.402 |
| Overige kosten
| 12.5 | 25 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bedrijfskosten
| 157.332 | 120.196 | 68.275 | 32.999 | 22.081 | 11.916 | 4.772 | 1.143 |
| Bedrijfsresultaat
| -109.727 | -145.196 | -68.275 | -32.999 | -22.081 | -11.916 | -4.772 | -1.143 |
| Bedrijfsresultaat ratio
| -2.164 | 0 | 0 | 0 | 0 | -11.603 | 0 | 0 |
| Totaal overige inkomsten en kosten netto
| 122.624 | 5.221 | -1.295 | 0.832 | 2.993 | 1.027 | -3.148 | -0.007 |
| Inkomen voor belasting
| 12.897 | -139.975 | -69.57 | -32.167 | -19.088 | -10.889 | -7.92 | -1.15 |
| Inkomen voor belasting ratio
| 0.254 | 0 | 0 | 0 | 0 | -10.603 | 0 | 0 |
| Belastingkosten
| 1.965 | 34.048 | 2.729 | 1.645 | 0.576 | -0.02 | 0 | 0 |
| Nettowinst
| 10.932 | -139.975 | -69.57 | -32.167 | -19.088 | -10.889 | -7.92 | -1.15 |
| Nettowinstmarge
| 0.216 | 0 | 0 | 0 | 0 | -10.603 | 0 | 0 |
| WPA (Winst Per Aandeel)
| 0.4 | -5.49 | -3.13 | -1.71 | -1.2 | -0.97 | -1.48 | -0.27 |
| Verwaterde WPA
| 0.39 | -5.49 | -3.13 | -1.71 | -1.2 | -0.97 | -1.48 | -0.27 |
| EBITDA
| 17.904 | -145.196 | -65.309 | -30.316 | -18.114 | -10.748 | -4.634 | -1.141 |
| EBITDA ratio
| 0.353 | 0 | 0 | 0 | 0 | -11.465 | 0 | 0 |